To date, ipamorelins efficacy has only been tested in one phase 2 clinical trial, which was a small, proof of concept study that involved just 114 participants [5]
Food and Drug Administration (FDA) for weight loss, making them an option for someone with psoriatic arthritis who is also trying to lower their body weight
Furthermore, GLP-1 and glucose-dependent insulinotropic polypeptides have been shown to induce substance P release from sensory nerves expressing TRPV1 and TRPA1, broadening the potential pain modulation mechanisms of GLP-1 and suggesting their application in peripheral pain management 64
Zepbound is FDA-approved specifically for chronic weight management in adults with Obesity or overweight and certain weight-related conditions, so a diagnosis of Type 2 Diabetes is not required
In Europe, Supplementary Protection Certificates (SPCs) extend the duration of a patent by up to 5 years (with a potential additional 6-month extension for products that have undergone paediatric testing)
Inno Shred GLP-1 is marketed with a no shortcuts message that fits well with fitness culture